Marta  Batus  to  Prognosis
                            
                            
                                This is a "connection" page, showing publications  Marta  Batus  has written about  Prognosis.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.429
         
        
        
     
 
    
        
        - 
            Pulmonary metastasectomy in bone and soft tissue sarcoma with metastasis to the lung. Interact Cardiovasc Thorac Surg. 2021 11 22; 33(6):879-884.
            
            
                Score: 0.154
             
- 
            Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
            
            
                Score: 0.071
             
- 
            Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS). Surg Oncol. 2023 Aug; 49:101949.
            
            
                Score: 0.043
             
- 
            Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
            
            
                Score: 0.036
             
- 
            The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
            
            
                Score: 0.030
             
- 
            Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. Pediatr Blood Cancer. 2017 04; 64(4).
            
            
                Score: 0.027
             
- 
            Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
            
            
                Score: 0.024
             
- 
            Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
            
            
                Score: 0.022
             
- 
            Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
            
            
                Score: 0.021